Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07574073 | Jun 2026 → May 2028 expected | autoimmune hemolytic anemia, autoimmune thrombocytopenia | Qi deng | Not yet recruiting | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT07231250 | Jan → Sep 2026 overdue | diffuse large B-cell lymphoma | Li Zhiming | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07261215 | Jan → Oct 2026 expected | Epstein-Barr virus infection, disease related to hematopoietic stem cell transplant | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07206264 | Oct 2025 → Dec 2027 expected | mantle cell lymphoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07008053 | Jul 2025 → Jul 2027 expected | marginal zone lymphoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06757894 | Feb 2025 → Feb 2028 expected | follicular lymphoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06985472 | Nov 2024 → Dec 2025 overdue | marginal zone lymphoma | Li Zhiming | Recruiting | No outcome recorded |
| Phase 2 | NCT06642909 | Nov 2024 → Mar 2027 expected | idiopathic membranous glomerulonephritis | BioRay Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03485118 | May → Aug 2016 | diffuse large B-cell lymphoma | Zhejiang Hisun Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07830433 | Oct 2026 → Dec 2029 expected | membranous glomerulonephritis | BioRay Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07264894 | Dec 2025 → Dec 2027 expected | mantle cell lymphoma | Zhengzhou University | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07257510 | Aug 2025 → Aug 2028 expected | mantle cell lymphoma | Peking University Third Hospital | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT07677813 Background | Jun 2026 → Dec 2029 expected | MCD diffuse large B-cell lymphoma | Ou Bai, MD/PHD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07480863 Background | Oct 2025 → Oct 2029 expected | marginal zone lymphoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zuberitamab | “For relapsed refractory MCL patients who had received BTK inhibitors: selinexor 60mg once daily on days 1 and 8, zuberitamab 375 mg/m² on day 0, Dexamethasone 20 mg on days 1-3...” NCT07264894 ↗12“During the induction therapy phase, patients will receive 90 mg/m2 of bendamustine and 375 mg/m2 zuberitamab from cycles 1 to 3, followed by 150 mg of orelabrutinib and 375...” NCT07008053 ↗ “Zuberitamab: intravenously administered on day 1 of the cycle at a dose of 375mg/m2 every 28 days, once every cycle for cycles 1-6 and once every 2 cycles for cycles 7-12.” NCT06985472 ↗ “This study aims to select Zuberitamab, a human-mouse chimeric anti-CD20 monoclonal antibody, and the BTKi Orelabrutinib as combination therapy options.” NCT07574073 ↗ “Zuberitamab is a novel anti-CD20 monoclonal antibody that demonstrates enhanced antibody-dependent cellular cytotoxicity compared with rituximab.” NCT07206264 ↗ |
| Known as | HS006 | “Zuberitamab Injection (HS006)” NCT06642909 ↗ |
| Modality | Monoclonal antibody | “Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody (HS006)” NCT03485118 ↗ |
| Route | Intravenous | “HS006 375 mg per square meter (mg/m\^2),administered intravenously(IV)” NCT03485118 ↗ |